Prognostic ALL Marker : CD10 (CALLA), in Visit Clinic

CD10‑positive (CALLA) B‑cell acute lymphoblastic leukemia generally has a favorable prognosis, especially in children, with higher complete‑remission rates and improved event‑free and overall survival. Outcome still depends on age, presenting white blood count, cytogenetics (e.g., favorable TEL‑AML1 vs adverse Ph+), and early treatment response including minimal residual disease; adults may derive less benefit than pediatric patients.

CD10 (neprilysin) can serve as a prognostic marker in certain cancers, but its significance is context-dependent. In some tumours, CD10 expression correlates with aggressive behaviour, metastasis, or treatment response; in haematologic malignancies it helps subtype and risk-stratify disease. Its clinical value is complementary and must be interpreted alongside other markers, histology, and clinical features.

CD10 is called CALLA because CALLA stands for "common acute lymphoblastic leukemia antigen." It was first identified on blasts from common B‑cell precursor acute lymphoblastic leukemia, so researchers named it CALLA. Later it was standardized as CD10 and found to be a neutral endopeptidase (neprilysin) expressed in normal tissues and various cancers, but the historic leukemia-derived name persisted.

CALLA positive means cells express the Common Acute Lymphoblastic Leukemia Antigen (CALLA), also known as CD10. This immunophenotype indicates B‑cell precursor lineage, helps confirm diagnosis and monitor disease by flow cytometry, and is frequently seen in pediatric acute lymphoblastic leukemia. CALLA positivity often associates with better treatment response and prognosis, but significance depends on age, genetics and overall clinical context.

Yes—it's possible, but it depends on leukemia type and individual factors. Chronic leukemias (e.g., CLL, CML) often become long-term, manageable conditions with targeted therapy and many people live 20+ years. Acute leukemias (AML, ALL) are more aggressive; long-term survival can occur, especially after effective chemotherapy or stem-cell transplant, but outcomes vary by age, genetics, treatment response, and access to care.

A strong good prognostic factor in acute lymphoblastic leukaemia is achieving minimal residual disease (MRD) negativity after induction therapy. MRD negativity — assessed by sensitive methods (flow cytometry or PCR) — indicates very low or undetectable leukemic cells and is linked to higher event‑free and overall survival, guiding risk‑adapted therapy and predicting better long‑term outcomes.